Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 62 entries
View as:

Antigen-specific T Cells Against Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03356808 Org: User:
Start: 12/15/17 End: 12/31/20 Due: 12/31/21

Intervention of CAR-T Against Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03356795 Org: User:
Start: 11/15/17 End: 12/31/20 Due: 12/31/21

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03050190 Org: User:
Start: 07/31/13 End: 12/31/20 Due: 12/31/21

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Phase: N/A Priority: Normal
NCT ID: NCT03393962 Org: User:
Start: 12/01/17 End: 12/31/20 Due: 12/31/21

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03353428 Org: User:
Start: 11/15/17 End: 12/31/20 Due: 12/31/21

4SCAR-T Therapy Post CD19-targeted Immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04430530 Org: User:
Start: 06/01/20 End: 12/31/23 Due: 12/31/24

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03271632 Org: User:
Start: 07/15/17 End: 12/31/20 Due: 12/31/21

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT03170141 Org: User:
Start: 05/31/17 End: 12/31/27 Due: 12/31/28

Immunotherapy Treating GI Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03614650 Org: User:
Start: 07/01/18 End: 12/31/21 Due: 12/31/22

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT04276896 Org: User:
Start: 03/24/20 End: 12/31/24 Due: 12/31/25

Lentiviral Gene Therapy for CGD

Phase: N/A Priority: Normal
NCT ID: NCT03645486 Org: User:
Start: 07/01/18 End: 12/31/21 Due: 12/31/22

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Phase: N/A Priority: Normal
NCT ID: NCT04085159 Org: User:
Start: 09/01/19 End: 12/31/22 Due: 12/31/23

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

Phase: N/A Priority: Normal
NCT ID: NCT03351829 Org: User:
Start: 12/01/17 End: 12/31/20 Due: 12/31/21

Engineered Immune Effectors Against Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03362619 Org: User:
Start: 11/15/17 End: 12/31/20 Due: 12/31/21

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT03356782 Org: User:
Start: 12/01/17 End: 12/31/23 Due: 12/31/24

CD19/79b Bi-specific CAR-T Cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05436509 Org: User:
Start: 06/30/22 End: 06/30/26 Due: 06/30/27

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

Phase: N/A Priority: Normal
NCT ID: NCT05277753 Org: User:
Start: 03/15/22 End: 12/31/25 Due: 12/31/26

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

Phase: N/A Priority: Normal
NCT ID: NCT06435897 Org: User:
Start: 05/15/24 End: 12/31/27 Due: 12/31/28

Engineered Immune Effectors Against Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03362606 Org: User:
Start: 11/15/17 End: 12/31/20 Due: 12/31/21

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06435910 Org: User:
Start: 05/11/24 End: 12/31/27 Due: 12/31/28

Lentiviral FIX Gene Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03961243 Org: User:
Start: 06/01/20 End: 06/01/22 Due: 06/01/23

IT and IV Lentiviral Gene Therapy for X-ALD

Phase: N/A Priority: Normal
NCT ID: NCT03727555 Org: User:
Start: 10/30/18 End: 12/31/28 Due: 12/31/29

Immune Modulatory DC Vaccine Against Brain Tumor

Phase: N/A Priority: Normal
NCT ID: NCT03914768 Org: User:
Start: 03/31/19 End: 12/31/22 Due: 12/31/23

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Phase: N/A Priority: Normal
NCT ID: NCT03535246 Org: User:
Start: 07/01/18 End: 12/31/21 Due: 12/31/22

Multi-4SCAR-T Therapy Targeting Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04430595 Org: User:
Start: 06/01/20 End: 12/31/23 Due: 12/31/24